2-[3-azaniumyl-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[3-azaniumyl-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoate
• 化学式: C9H17NO7
• 分子量: 251.23
• InChiKey: MSFSPUZXLOGKHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  143
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] SYNTHETIC N-ACETYL-MURAMIC ACID DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE MURAMIQUE N-ACÉTYLÉ SYNTHÉTIQUES ET LEURS UTILISATIONS
  申请人：UNIV DELAWARE

  公开号：WO2016172615A1

  公开（公告）日：2016-10-27

  The present invention provides N-acetyl-muramic acid (NAM) derivatives having Formula I, wherein Xa is selected from the group consisting of X1-X59, Ya is selected from the group consisting of H, monophosphate, uridine diphosphate and ethyl azide linker prepared from 2-azido-ethanol, and Za is selected from the group consisting of OH, an ethylene diamine coupled fluorophore, a peptide and a peptide with an ethylene diamine coupled fluorophore, wherein the peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide and a pentapeptide. Also provided are methods for synthesizing NAM derivatives and methods for modulating Nod2 in cells, modifying bacterial cell wall or modulating innate immune response by a subject to bacterial cells upon exposure to NAM derivatives.

  本发明提供具有式I的N-乙酰-壳聚糖酸（NAM）衍生物，其中Xa选自X1-X59组，Ya选自H、磷酸单酯、尿苷二磷酸和由2-叠氮乙醇制备的乙基叠氮连接剂组，Za选自OH、乙二胺偶联的荧光素、肽和乙二胺偶联的肽，其中肽选自单肽、二肽、三肽和五肽组。还提供了合成NAM衍生物的方法以及通过暴露于NAM衍生物后调节细胞中Nod2、修改细菌细胞壁或调节受试者对细菌细胞的固有免疫反应的方法。
• [EN] USE OF A NEW CLASS OF NUCLEOTIDE SUGAR AS ANTIBIOTIC OR CYTOSTATIC AGENT<br/>[FR] UTILISATION D'UNE NOUVELLE CATÉGORIE DE SUCRE DE NUCLÉOTIDE EN TANT QU'ANTIBIOTIQUE OU AGENT CYTOSTATIQUE
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2012038097A1

  公开（公告）日：2012-03-29

  The present invention relates to the use of a compound of the formula (A), its use in medicine and for the prophylaxis and/or treatment of infectious diseases. Also disclosed are pharmaceutical formulations containing at least one of the inventive compounds. The compounds are especially useful for prophylaxis and/or treatment of bacterial infection. Further part of the invention is a method for producing the compounds of the formula (A)

  本发明涉及一种公式（A）的化合物的使用，其在医学上的应用以及用于预防 和/或治疗传染性疾病。还公开了包含至少一种本发明的化合物的药物制剂。这些化合物特别适用于预防 和/或治疗细菌感染。发明的另一部分是一种生产公式（A）化合物的方法
• [EN] AMPHETAMINE PRODRUGS<br/>[FR] PRO-MÉDICAMENTS À BASE D'AMPHÉTAMINES
  申请人：SHIRE AG

  公开号：WO2014002039A1

  公开（公告）日：2014-01-03

  The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.

  本发明涉及提供苯丙胺结肠释放的苯丙胺前药。
• [EN] COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LA THÉRAPIE CELLULAIRE ADOPTIVE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：WO2019006467A1

  公开（公告）日：2019-01-03

  Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

  本文提供了一种采用工程免疫细胞的细胞治疗组合物和方法，这些免疫细胞表达靶向抗原的嵌合抗原受体和一种前药转化酶，用于治疗炎症、炎症性疾病或病原体感染。